-
公开(公告)号：US20230181824A1
公开(公告)日：2023-06-15
申请号：US18159353
申请日：2023-01-25
Applicant: INSULET CORPORATION
Inventor： Jason O'CONNOR , Joon Bok LEE , Trang LY , Yibin ZHENG , Thomas Arnold PEYSER , Jennifer Lena SCHNEIDER
CPC classification number: A61M5/1723 , A61B5/14532 , A61M5/14244 , A61M5/145 , A61B5/486
Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.
-
公开(公告)号：US20230173173A1
公开(公告)日：2023-06-08
申请号：US18160724
申请日：2023-01-27
Applicant: INSULET CORPORATION
Inventor： Jason O'CONNOR , Joon Bok LEE , Ian MCLAUGHLIN , John D'ARCO
CPC classification number: A61M5/158 , A61B5/14532 , A61B5/4839 , A61M5/14244 , A61M31/002 , A61B2562/0219 , A61M2005/14208 , A61M2005/14252 , A61M2005/1585
Abstract: A drug delivery device may include an Inertial Measurement Unit (IMU) is provided. The IMU may include an accelerometer, a magnetometer, or a gyroscope. Motion parameters may be detected when the drug delivery device is shipped, being prepared for activation for use, or during use. The IMU may provide data indicative of a rapid deceleration, such as when a package containing the drug delivery device is dropped, or some other physical event experienced by the drug delivery device. The drug delivery device may also include internal or external pressure sensors or a blood glucose sensor that may coordinate with the IMU to provide additional feedback regarding the status of the device or user. A controller of the drug delivery device may generate a response depending on the particular parameters being monitored or may change device operational parameters as a result of detected system events.
-
公开(公告)号：US20230162833A1
公开(公告)日：2023-05-25
申请号：US18151582
申请日：2023-01-09
Applicant: INSULET CORPORATION
Inventor： David NAZZARO , Steven CARDINALI , Nicholas CONTE , Daniel ALLIS , Jason O'CONNOR , Joon Bok LEE , Ashutosh ZADE , Timothy HENNING , Thomas METZMAKER , Ian MCLAUGHLIN
Abstract: Disclosed are examples of a device, a system, methods and computer-readable medium products operable to implement functionality to determine and respond to a purpose of a meal. An algorithm or application may receive data that may include data related to a meal purpose from data sources and determine whether any of the data received from the plurality of data sources was received from a direct data source or an indirect data source. The data may be evaluated to determine a purpose of the meal. Based on the results of the evaluation, instructions may be generated to provide an appropriate response based on the determined purpose of the meal. The generated instructions to provide the appropriate response based on the determined purpose of the meal may be output.
-
公开(公告)号：US20230060939A1
公开(公告)日：2023-03-02
申请号：US17821653
申请日：2022-08-23
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Ashutosh ZADE , Yibin ZHENG , Jason O'CONNOR
Abstract: The insulin to carbohydrate ratio (ICR) and the correction factor for a user of a medicament delivery device may be automatically adjusted. The automatic adjustments may tailor the values to the user's actual insulin needs. Various factors may be examined to determine how to adjust the ICR and the correction factor. The identified factors are weighed with the processor to decide whether to increase or decrease the insulin to carbohydrate ratio or the correction factor. The insulin to carbohydrate ratio or the correction factor for the user are adjusted based on the weights of the identified factors. In addition or in the alternative, automatic adjustments of user-requested insulin boluses may be made to requested dosages and timing of deliveries of the insulin boluses. In some instances, the exemplary embodiments may deliver a percentage of the insulin bolus dosage initially and deliver the remaining percentage after a delay to reduce the risk of hypoglycemia for the user.
-
85.发明申请公开(公告)号：US20230011699A1
公开(公告)日：2023-01-12
申请号：US17860609
申请日：2022-07-08
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Matthew ALLES , Yibin ZHENG , Jason O'CONNOR
IPC: A61M5/172
Abstract: Provided are techniques, devices and systems that include monitoring a trend of blood glucose measurement values over a series of measurement cycles. A processor may identify a potential excursion outside a range of a target blood glucose measurement value setting of a user based on the monitored trend. In response to the identified potential excursion, an alert may be generated to the user to consume rescue carbohydrates. In addition, the disclosed techniques may include a processor that assesses the factors related to a potential impending hypoglycemic event for a user. Based on a result of the assessment of the factors, the processor may determine whether the user is approaching the potential impending hypoglycemic event for the user. In response to a determination that the user is approaching the potential impending hypoglycemic event for the user, a number of rescue carbohydrates to suggest for consumption by the user may be determined.
-
Patent Agency Ranking
86.发明申请公开(公告)号：US20220241504A1
公开(公告)日：2022-08-04
申请号：US17582349
申请日：2022-01-24
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Jason O'CONNOR , Yibin ZHENG , Ashutosh ZADE
Abstract: Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.
-
公开(公告)号：US20220240847A1
公开(公告)日：2022-08-04
申请号：US17582374
申请日：2022-01-24
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Jason O'CONNOR , Yibin ZHENG , Ashutosh ZADE
Abstract: Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.
-
公开(公告)号：US20210379282A1
公开(公告)日：2021-12-09
申请号：US17403784
申请日：2021-08-16
Applicant: Insulet Corporation
Inventor： Jason O'CONNOR , Daniel ALLIS , David NAZZARO , John R. Bussiere , John D'ARCO
Abstract: Systems and methods for automatically delivering medication to a user. An automated drug delivery system may include a sensor and a wearable automated drug delivery device. The wearable automated drug delivery device may be configured to couple to the skin of a user and may include a controller and a pump. The pump may be configured to output the medication. The controller may be within the wearable automated drug delivery device. The sensor may be coupled to the user and may be configured to collect information regarding the user. The controller of the wearable automated drug delivery device may use the collected information to locally determine an amount of medication to be output from the wearable automated drug delivery device and cause delivery of the amount of medication.
-
公开(公告)号：US20210236726A1
公开(公告)日：2021-08-05
申请号：US16780278
申请日：2020-02-03
Applicant: Insulet Corporation
Inventor： Steven CARDINALI , Ashutosh ZADE , Joon Bok LEE , Jason O'CONNOR , Yibin ZHENG
IPC: A61M5/172
Abstract: Exemplary embodiments may provide an improved approach to automated insulin delivery by more accurately estimating the total daily insulin (TDI) of a user. As a result, less insulin is wasted by the delivery system, and the estimate of TDI more closely matches a user's actual daily insulin needs. Hence, the user need not refill the insulin reservoir excessively or need not fret unnecessarily about running out of insulin prematurely. The estimate relies on the history of actual automated insulin deliveries and thus reflects the actual insulin delivered to the user more accurately than conventional approaches.
-
公开(公告)号：US20210098105A1
公开(公告)日：2021-04-01
申请号：US16586499
申请日：2019-09-27
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , Trang LY , Eric BENJAMIN
Abstract: Disclosed are a device, a computer-readable medium, and techniques that provide an onboarding process and an adaptivity process for a drug delivery device. A processor executing an onboarding process determines whether a history of delivered insulin to a user meets certain sufficiency requirements. The onboarding process enables a processor to cause the drug delivery device to administer doses of insulin to a user according to an initial total daily insulin dose calculation that is determined based on the sufficiency of the insulin delivery history. The initial total daily insulin may be adapted according to the adaptivity process as new insulin delivery is collected. The insulin delivery history, when sufficient, may be used to set total daily insulin dosages that enable automated insulin delivery upon replacement of a drug delivery device. The adaptivity process may be implemented to modify an initial insulin delivery doses to provide adapted insulin delivery doses.
-
-
-
-
-
-
-
-
-
Search Results
93
records
(took 0.022 seconds)
